课题基金 / 基金详情

肺炎克雷伯菌噬菌体KP-C01识别多种宿主表面受体的分子机制

批准号:
32100113
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
程梦珺
依托单位:
学科分类:
病毒学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
程梦珺

项目摘要

结项摘要

相似基金

相关文献

中文摘要
噬菌体结构和遗传多样性及宿主受体的复杂性决定了二者的互作机制必然是多样且复杂的。本项目前期研究中发现,肺炎克雷伯菌噬菌体KP-C01识别细菌8110W-B的多糖和噬菌体耐受菌C01R-122R的蛋白受体,而与其相似性极高的KP100仅识别前者,但具体受体和分子机制仍不清楚。初步判定KP-C01和KP100中ORF48编码的尾针蛋白为其各自的受体结合蛋白(RBP),推测二者之间的某些差异导致了其识别受体的不同。本研究将通过原核表达和竞争吸附确定两株噬菌体的RBP;对亲本株和耐受噬菌体突变株进行差异基因组、蛋白质组分析及pull down实验确定两株噬菌体识别的宿主受体,并利用基因敲除与回补进行验证;根据同源建模和活性预测结果,表达RBP的不同截短及单位点突变蛋白确定其识别受体的关键结构域和氨基酸位点。本研究对丰富噬菌体与宿主的互作机制具有重要意义,也为改造噬菌体以拓宽其裂解谱提供理论依据。
英文摘要
The diversity of phages structure and genetic and the complexity of host receptors determine that the interaction mechanisms between phages and host must be diverse and complex. In the previous study of this project, it was found that Klebsiella pneumoniae phage KP-C01 could recognize the polysaccharide receptor of bacteria 8110W-B and the protein receptor of phage-resistant bacteria C01R-122R, while KP100, which is very similar to it, only recognized the former receptor, but the specific receptors and mechanism of action was still unclear. It was preliminarily determined that the tail spike encoded by ORF48 in KP-C01 and KP100 were their respective receptor binding proteins (RBPs) and it was speculated that some differences between the two RBPs led them to recognize different host receptors. In this study, RBP in two phages was determined by prokaryotic expression and competitive adsorption experiment. Differentially genomic, proteomic and pull down analysis were performed on the wild-type strains and the phage-resistant mutant strains to determine the host receptors recognized by the two phages, and gene knockout and complement were used for verification. Based on homology modeling and activity prediction, different truncated proteins and unit point mutations of RBP were expressed to identify the key domains and amino acid sites of the receptor recognition. This study is of great significance for enriching the interaction mechanism between phages and host, and also provides a theoretical basis for modifying phage to broaden its lytic spectrum.
噬菌体治疗是对抗耐药细菌感染的有力武器。但噬菌体宿主窄、易产生耐受是阻碍噬菌体治疗发展的关键问题。选择不同受体的噬菌体组合既可以拓宽宿主谱又可以在一定程度上减少耐受的发生,提高噬菌体治疗的成功率。本项目的研究成功证实了噬菌体KP100和KPC01可以以肺炎克雷伯菌8110W-B表面KL102型的荚膜多糖作为受体,噬菌体编码的尾丝蛋白为其受体结合蛋白,可以特异性结合并水解细菌表面荚膜多糖。当细菌肺炎克雷伯菌8110W-B耐受KP-C01后,噬菌体KP122可以细菌表面LPS为受体侵染耐受菌。通过细菌与噬菌体的共进化,已初步鉴定出噬菌体KP122的可能得RBP及关键位点。但是本项目还有很多问题没有解决,如KPC01识别多位点的分子机制的解析、噬菌体KP122的RBP具体识别机制的明确等,仍然需要进一步的研究。本研究的结果可以对丰富噬菌体与宿主的互作机制,同时为人工噬菌体的合成改造、噬菌体治疗时鸡尾酒配方的选择都可以提供一定的理论基础和指导意义。
国内基金
海外基金